New Certified Wind Turbine for FIT Scheme Announced

Green energy

New Certified Wind Turbine for FIT Scheme Announced

30 Aug, 2012

Published over 13 years ago. See the latest and most current information on Green energy.

Kestrel have recently launched their newest small wind turbine to complete certification for the Department of Energy and Climate Change (DECC) Feed-In Tariff (FIT). This is the first class one wind turbine (less than 5kW) but can withstand wind speeds of up to 156mph generating around £1000 for users annually.

The certified Kestrel e400nb can produce 3,922kWh annually, and with the FIT scheme paying 28p per kWh produced, you can earn £1,098 per year, be less reliant on the grid, and eco-friendly.

Conducted by MCS Certification (MCS) on behalf of the UK Government, it focuses on ensuring the quality of renewable technology installations and products.

“Solid returns from renewable energy, new technology and improved Government incentives, makes it easier to become less reliant on fossil fuels.” Commented Kestrel Director Leon Gouws. “The UK Government’s target for 20 per cent of the energy to be produced from renewable sources by 2020, and the certification process means people can support this vision, with knowledge their turbine is robust enough to withstand the toughest of winds, and is reliable to ensure consistent energy production.”

The Kestrel 3.5kW small wind turbines are ideal for homes or small businesses with the available space for installation. Tested by TUV NEL in East Kilbride, Scotland, the small wind turbine was tested and withstands winds of 156.6mph.

Latest News

Explore Our Other Sites

Labmate Online
Microneedle patch enables real-time drug monitoring
Explore more Arrow
Envirotech Online
New civil penalties and real-time monitoring raise the bar for water company compliance
Explore more Arrow
Petro Online
Fifty years on, the EU reaffirms its commitment to Seveso-level industrial safety oversight
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow